Recruiting PHASE4 INTERVENTIONAL 2-arm NCT07139366

Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment

Efficacy and Safety of Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment: A Prospective, Multicenter, Randomized Controlled Trial

Sponsor: Yongquan Shi

Conditions Dyspepsia Gastric Cancer Gastritis Helicobacter Pylori Infection Peptic Ulcer

Interventions Bismuth Esomeprazole Furazolidone Saccharomyces Boulardii Oral Powder Tetracycline

Updated 2 times since 2025 Last updated: Nov 30, 2025 Started: Oct 28, 2025 Primary completion: Sep 30, 2026 Completion: Sep 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07139366, this PHASE4 trial focuses on Dyspepsia and Gastric Cancer and remains actively recruiting participants. Sponsored by Yongquan Shi, it has been updated 2 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

2 versions recorded

Jan 2026 — Present [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Sep 2025 — Jan 2026 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Yongquan Shi

Data source: Xijing Hospital of Digestive Diseases

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Xi'an, China